• 1. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 2. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 3. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565

Recent Advances in the Study of (1-Benzyl-piperidin-4-ylmethyl)-ethyl-amine (CAS: 92566-75-1) in Chemical Biology and Pharmaceutical Research

The compound (1-Benzyl-piperidin-4-ylmethyl)-ethyl-amine (CAS: 92566-75-1) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. This molecule, characterized by its piperidine scaffold and benzyl substitution, has been investigated for its role as a modulator of various biological targets, including neurotransmitter receptors and enzymes involved in signal transduction pathways. Recent studies have explored its pharmacological properties, synthesis methods, and potential as a lead compound for drug development.

One of the key areas of research has focused on the compound's interaction with the central nervous system (CNS). Preliminary findings suggest that (1-Benzyl-piperidin-4-ylmethyl)-ethyl-amine exhibits affinity for serotonin and dopamine receptors, which could make it a candidate for treating neurological disorders such as depression and Parkinson's disease. Additionally, its structural similarity to known pharmacophores has prompted investigations into its potential as an analgesic or anti-inflammatory agent. Researchers have employed computational modeling and in vitro assays to elucidate its binding mechanisms and optimize its activity profile.

Recent advancements in synthetic chemistry have also facilitated the development of novel derivatives of (1-Benzyl-piperidin-4-ylmethyl)-ethyl-amine. These derivatives are designed to enhance bioavailability, reduce toxicity, and improve target specificity. For instance, a 2023 study published in the Journal of Medicinal Chemistry reported the synthesis of a series of analogs with modified benzyl and ethylamine moieties, demonstrating improved pharmacokinetic properties in preclinical models. Such innovations highlight the compound's versatility and potential for further optimization.

In addition to its CNS applications, (1-Benzyl-piperidin-4-ylmethyl)-ethyl-amine has been explored for its role in oncology. A recent study in Bioorganic & Medicinal Chemistry Letters revealed that certain derivatives of this compound exhibit inhibitory effects on cancer cell proliferation by targeting specific kinases involved in tumor growth. These findings open new avenues for the development of targeted cancer therapies, particularly for malignancies resistant to conventional treatments.

Despite these promising developments, challenges remain in translating these discoveries into clinical applications. Issues such as metabolic stability, off-target effects, and scalability of synthesis need to be addressed. Future research directions may include the use of advanced drug delivery systems, such as nanoparticles or prodrug formulations, to overcome these limitations. Collaborative efforts between chemists, biologists, and clinicians will be essential to fully realize the therapeutic potential of (1-Benzyl-piperidin-4-ylmethyl)-ethyl-amine and its derivatives.

In conclusion, (1-Benzyl-piperidin-4-ylmethyl)-ethyl-amine (CAS: 92566-75-1) represents a promising scaffold in chemical biology and pharmaceutical research. Its diverse biological activities and potential for structural modification make it a valuable candidate for further investigation. As research progresses, this compound may pave the way for novel treatments in neurology, oncology, and beyond, underscoring the importance of continued exploration in this field.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)